Skip to main content
OpenTrials
Completed

NCT Number: NCT02636023

Correlation Between the SPhENo-Cardiograph™, a Seismocardiograph Device, and GE Vivid Q, an Echocardiograph, for Known Systemic Timing Intervals (STI)

The study Sponsor, Heart Force Medical Inc. (HFM), has developed a patented medical device called the SPhENo-CardiographTM. The SPhENo-Cardiograph™ provides a non-invasive assessment of the electro-mechanical function of the heart. The electrocardiograph (ECG) represents the waveform of the electrical stimulus to the cardiac muscle. The mechanical actions of the electrical potentials delivered in the ECG are revealed as the seismocardiograph (SCG). The SCG represents the changes in acceleration of the heart during the cardiac cycle. The SCG waveform reflects the ultra-low frequency vibrations of cardiac contraction. These low frequency vibrations are transmitted through the sternum. Using the point of initiation of ventricular contraction on the ECG, the Q wave, with fiduciary points on the synchronous seismocardiograph, it is possible to determine timing events of the cardiac cycle. The timing events of the cardiac cycle during systole are referred to as Systolic Timing Intervals (STI) and comprise the Pre-Ejection Period (PEP) and the Left Ventricular Ejection Time (LVET). The PEP is the time from the Q wave to the Aortic valve opening. The Left Ventricular Eject Time (LVET) is the time between the Aortic Valve opening and closing. The ratio of PEP/LVET in individuals with established heart disease is > 0.42. It is based on the formula described by Dr Arnold Weissler and first published in Circulation in 1968 (Weissler et al,1968). Weissler et al showed that the PEP/LVET ratio >0.42 are indicative of a lengthening of the PEP with some marginal shortening of the LVET. This is indicative of pathology associated with the coronary circulation (Ahmed et al, 1972;). This ratio can then be used as part of a non-invasive quantitative assessment of cardiac performance (Lewis et al 1977).

Using the SPhENo-CardiographTM, HFM has developed an algorithm to assess heart health that otherwise requires a number of technologies; stethoscope, ECG and Carotid pulse tracing to identify the dicrotic notch or Aortic Valve closure.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Boucher Institute of Naturopathic Medicine

New Westminster, British Columbia, V3L 5N8, Canada

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to understand the informed consent document
  • Willing to participate in study
  • Ambulatory volunteer

Exclusion criteria

  • Individuals with visible scar(s) or deformity in the test area of the chest
  • Non-ambulatory subjects
  • Previously diagnosed with life-threatening condition (e.g. cancer)
  • Known or diagnosed psychiatric condition
  • Enrolled in a concurrent study or trial
  • Exercised excessively within the last 4 hours (prior to study visit)
  • Consumption of caffeine containing drinks within the previous 4 hours
  • Unwilling to sign Informed Consent
  • Female subjects who are pregnant, suspected or planning to become pregnant or breast-feeding

Treatment and study plan

SPhENo-Cardiograph

Device

SPhENo-Cardiograph

Primary outcomes

  1. Correlation coefficient ≥0.8 between STI ratio values determined by the SPhENo-Cardiograph™ and an echocardiograph

    Time frame: 1 day

  2. Correlation coefficient ≥0.8 between PEP values determined by the SPhENo-Cardiograph™ and an echocardiograph

    Time frame: 1 day

  3. Correlation coefficient ≥0.8 between LVET values determined by the SPhENo-Cardiograph™ and an echocardiograph

    Time frame: 1 day

  4. Correlation coefficient ≥0.8 between heart rate values determined by the SPhENo-Cardiograph™ and an echocardiograph

    Time frame: 1 day

Secondary outcomes

  1. Correlation coefficient ≥0.8 between STI ratio values determined by the SPhENo-Cardiograph™ and a manual analysis

    Time frame: 1 day

  2. Correlation coefficient ≥0.8 between PEP values determined by the SPhENo-Cardiograph™ and a manual analysis

    Time frame: 1 day

  3. Correlation coefficient ≥0.8 between LVET values determined by the SPhENo-Cardiograph™ and a manual analysis

    Time frame: 1 day

  4. Correlation coefficient ≥0.8 between heart rate values determined by the SPhENo-Cardiograph™ and a manual analysis

    Time frame: 1 day

  5. Safety and tolerability assessed by Adverse event collection

    Time frame: 1 day

    Adverse event collection

  6. Subject questionnaire

    Time frame: 1 day

    Questionnaire to evaluate relevance of device from subject's perspective; data to be analyzed qualitatively

Sponsors and collaborators

Lead sponsor

Heart Force Medical Inc.

Industry

Registry information

Official study title

A Clinical Study to Determine the Correlation Between the SPhENo-Cardiograph™, a Seismocardiograph Device, and GE Vivid Q, an Echocardiograph, for Known Systemic Timing Intervals (STI).

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Dec 21, 2015
Registry last updated
Feb 11, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.